# ABOLIS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abolis

- Industry: Biotechnology
- Headquarters: Evry, France
- Website: www.abolis.fr
- Total disclosed funding: $11M
- Latest round: Series A (Aug 7, 2024)
- Investors on record: 6

## About

Founded in 2014 and based in Evry, France, ABOLIS operates as a biotechnology company. In September 2024, ABOLIS raised EUR 35 million in Series A funding co-led by Bold, Evonik Venture Capital, Deep Tech & Climate Fund, Clay Partners, ICOS Capital, and Liberset. The company was founded by its CEO, Cyrille Pauthenier, Valérie Brunel.

ABOLIS specializes in providing industrial solutions using natural and modified microorganisms for various industries, including food, healthcare, cosmetics, and chemistry. The company develops and offers biosynthesis processes to transform microorganisms to produce complex molecular entities. The company uses microorganisms to produce small molecules, proteins, and microbiomes for a variety of applications.

The company plans to utilize the September 2024 funding to grow its product line, expedite its development, scale up its biomanufacturing operations, and broaden the scope of the Microbiome Studio business unit devoted to understanding and manipulating microbial ecosystems.

## Funding rounds

- Series A, Aug 7, 2024, $11M — ICOS Capital, Clay Capital, Evonik Venture Capital, BOLD, Liberset, DeepTech and Climate Fund

## Investors

- ICOS Capital (https://capitalatlas.ai/funds/icos-capital) — Series A
- Clay Capital (https://capitalatlas.ai/funds/clay-capital) — Series A
- Evonik Venture Capital (https://capitalatlas.ai/funds/evonik-venture-capital) — Series A
- BOLD — Series A
- Liberset (https://capitalatlas.ai/funds/liberset) — Series A
- DeepTech and Climate Fund (https://capitalatlas.ai/funds/deeptech-and-climate-fund) — Series A